IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Design Therapeutics Inc. DSGN stock surged during the premarket session on Monday. The move came after the company reported ...
Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the ...
Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...
Rare conditions can be daunting, terrifying and isolating. For the people and families affected by them, the search for a ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 ...
For people with a progressive genetic condition called Friedreich ataxia, which affects nerves and muscles, taking medicine for a year probably has little to no effect on measures of ataxia (problems ...
aUnité de Médecine Interne (UF04): CRMR MATHEC, Maladies Auto-immunes et Thérapie Cellulaire, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Nord-Université de Paris, Paris, France ...
Researchers have uncovered a fundamental rule that governs how genes are physically arranged inside the cell nucleus, and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results